FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors – PR Newswire

  1. FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors  PR Newswire
  2. European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors  Yahoo Finance
  3. FDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older  Contemporary Pediatrics
  4. Novo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B  Insider Monkey
  5. European Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia  Docwire News

Source link
Related Articles

Related posts:

  1. New leukemia drug offers hope for children and adults
  2. Cabinet approves call for local bids to supply medicines in 2026
  3. FDA to consider warning against antidepressants | National
  4. FDA considers removing warning labels on hormone replacement therapies : Shots
See also  Columbia University disciplines at least 70 students who took part in campus protests
↑
Exit mobile version